Cirrhosis Clinical Trial
— CHESS2204Official title:
The Value of Baveno VI Criteria for Screening and Monitoring of Varices Needing Treatment in Patients With Compensated Cirrhosis
Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000 are considered to have very low risk of having varices requiring treatment, but whether these patients can be followed up by repetition of this criteria lacks sufficient evidence. This study aimed to assess the value of Baveno VI criteria for following up and monitoring of varices needing treatment in patients with compensated cirrhosis.
Status | Not yet recruiting |
Enrollment | 1000 |
Est. completion date | December 2023 |
Est. primary completion date | December 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. Patients with liver cirrhosis diagnosed according to clinical or pathological criteria; 2. No decompensation events in the past, no ascites shown by ultrasound, no significant abnormality in liver function and coagulation function; 3. Willing to carry out routine diagnosis and treatment evaluation and follow-up liver stiffness test and gastroscopy; 4. Patients meet Baveno VI criteria (with a liver stiffness <20kPa and with a platelet count >150,000) at baseline, or patients don't meet Baveno VI criteria (with a liver stiffness = 20kPa or with a platelet count =150,000) at baseline, but don't have varices requiring treatment (proved by endoscopy). 5. Voluntarily signed the informed consent. Exclusion Criteria: 1. Patients with liver carcinoma; 2. Patients with portal vein thrombosis; 3. Patients with varices requiring treatment confirmed by gastroscopy during the screening period; 4. Patients who have received propranolol, ligation, sclerosis, splenectomy, transcatheter splenic arterial embolization, transjugular interhepatic portosystemicstent-shunt and other treatments to decrease portal hypertension in the past. |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Huashan Hospital | Beilun Hospital of Chinese Medicine, Fifth Hospital of Shijiazhuang City, First Affiliated Hospital of Fujian Medical University, Gansu Wuwei Tumor Hospital, Liuzhou Workers Hospital, Nanjing Hospital of Chinese Medicine affiliated to Nanjing University of Chinese Medicine, Shenzhen Third People's Hospital, Taizhou People's Hospital, The Affiliated Hospital of Xuzhou Medical University, The Fifth People's Hospital of Wuxi Affiliated Hospital of Jiangnan University, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of Xian Jiaotong University, The First People's Hospital of Taicang, The Fourth People's Hospital of Qinghai Province, The Sixth Hospital of Dalian, The Sixth Hospital of Qingdao, The Third Affiliated Hospital of Hebei Medical University, The Third People's Hospital of Linfen City, The Third People's Hospital of Taiyuan, Xinjiang Hospital of Chinese Medicine |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The missing rate of Baveno criteria at 12th month follow-up visit | The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 12th month follow-up visit | 12 months from baseline | |
Secondary | The missing rate of Baveno criteria at 24th month follow-up visit | The number of patients with varices requiring treatment under endoscopy divided by the number of patients meet Baveno criteria at 24th month follow-up visit | 24 months from baseline | |
Secondary | Cumulative rate of decompensation events | The cumulative rate of decompensated events in all participants during the 24 months. | 24 months from baseline | |
Secondary | Cumulative rate of gastrointestinal bleeding | The cumulative rate of gastrointestinal bleeding in all participants during the 24 months. | 24 months from baseline | |
Secondary | Cumulative rate of 6-week death post gastrointestinal bleeding | The cumulative rate of death in 6 weeks post gastrointestinal bleeding in patients with gastrointestinal bleeding events during the 24 months. | 24 months from baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A | |
Terminated |
NCT00375011 -
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
|